Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update
Luca Zagaroli, Alessio Di Berardino, Francesco Petragnano, Serena Lustri, Irene Fasciani, Mario Rossi, Marco G Baroni, Maurizio Delvecchio · 2026
Read Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update by Luca Zagaroli, Alessio Di Berardino, Francesco Petragnano, Serena Lustri, Irene Fasciani, Mario Rossi, Marco G Baroni, Maurizio Delvecchio (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13388877.txt.
Description
Luca Zagaroli and co-authors update, in 2026, the evidence on drug treatment for maturity-onset diabetes of the young, known as MODY. MODY is a rare inherited form of diabetes caused by a single gene change, and the right gene result can point to the right drug and spare patients needless treatment.
Following standard review methods, the team searched for studies from April 2020 to October 2025 and included 91 reports on patients with confirmed gene changes. Strong support remains for sulfonylurea drugs in the most common gene forms, and newer options are reviewed gene by gene. Diabetes specialists and families affected by MODY will find a current guide to matching treatment to the exact genetic cause.
Catalog record
| CREATOR | Luca Zagaroli, Alessio Di Berardino, Francesco Petragnano, Serena Lustri, Irene Fasciani, Mario Rossi, Marco G Baroni, Maurizio Delvecchio |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62786 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |